series-b
Stage
2
Investors
About
SurgeTx develops an injectable biodegradable hydrogel that delivers localized cancer immunotherapy at the site of surgical tumor resection to prevent post-surgical cancer recurrence and metastasis.
Explore SurgeTx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.